Danaher Corporation (NYSE:DHR) Shares Bought by Sumitomo Mitsui Trust Holdings Inc.

Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Danaher Corporation (NYSE:DHR) by 5.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,011,781 shares of the conglomerate’s stock after purchasing an additional 97,197 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.29% of Danaher worth $172,571,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of DHR. National Asset Management Inc. raised its stake in shares of Danaher by 0.4% during the 2nd quarter. National Asset Management Inc. now owns 3,767 shares of the conglomerate’s stock valued at $318,000 after buying an additional 14 shares during the last quarter. First Financial Corp IN grew its position in shares of Danaher by 0.8% during the 2nd quarter. First Financial Corp IN now owns 2,720 shares of the conglomerate’s stock valued at $230,000 after acquiring an additional 21 shares during the period. Brighton Jones LLC grew its position in shares of Danaher by 0.4% during the 2nd quarter. Brighton Jones LLC now owns 5,159 shares of the conglomerate’s stock valued at $435,000 after acquiring an additional 21 shares during the period. Guardian Life Insurance Co. of America grew its position in shares of Danaher by 1.0% during the 1st quarter. Guardian Life Insurance Co. of America now owns 2,356 shares of the conglomerate’s stock valued at $202,000 after acquiring an additional 24 shares during the period. Finally, Buckingham Asset Management LLC grew its position in shares of Danaher by 0.4% during the 2nd quarter. Buckingham Asset Management LLC now owns 5,778 shares of the conglomerate’s stock valued at $488,000 after acquiring an additional 24 shares during the period. 76.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Danaher Corporation (NYSE:DHR) opened at $92.82 on Tuesday. The company has a market cap of $65,261.68, a P/E ratio of 24.12, a PEG ratio of 2.23 and a beta of 1.02. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Corporation has a 12-month low of $76.27 and a 12-month high of $94.82.

Danaher (NYSE:DHR) last announced its earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. The company had revenue of $4.53 billion for the quarter, compared to analyst estimates of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The firm’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.87 earnings per share. analysts forecast that Danaher Corporation will post 3.99 earnings per share for the current year.

In related news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the completion of the transaction, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Daniel L. Comas sold 88,184 shares of the business’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the transaction, the chief financial officer now owns 227,816 shares of the company’s stock, valued at approximately $20,735,812.32. The disclosure for this sale can be found here. Insiders have sold 273,810 shares of company stock worth $25,218,813 in the last ninety days. Corporate insiders own 12.20% of the company’s stock.

DHR has been the topic of a number of analyst reports. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price on the stock in a research report on Thursday, October 5th. Cowen restated a “buy” rating and set a $90.00 target price on shares of Danaher in a research report on Wednesday, October 4th. Goldman Sachs Group restated a “neutral” rating and set a $83.00 target price on shares of Danaher in a research report on Tuesday, September 26th. Robert W. Baird lifted their price objective on Danaher from $87.00 to $97.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. Finally, Credit Suisse Group lifted their price objective on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a report on Friday, October 20th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Danaher currently has a consensus rating of “Buy” and an average price target of $93.31.

COPYRIGHT VIOLATION WARNING: This story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/12/05/danaher-corporation-dhr-position-raised-by-sumitomo-mitsui-trust-holdings-inc.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply